Cargando…

PRIMA-1(MET) Inhibits Growth of Mouse Tumors Carrying Mutant p53

Reactivation of the tumor suppressor activity to mutant p53 should trigger massive apoptosis and eliminate tumors. The low molecular weight compounds PRIMA-1 and the structural analog PRIMA-1(MET) reactivate human mutant p53 in vitro and suppress growth of human tumor xenografts in SCID mice. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zache, Nicole, Lambert, Jeremy M. R., Wiman, Klas G., Bykov, Vladimir J. N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2008
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618963/ https://www.ncbi.nlm.nih.gov/pubmed/18791272 http://dx.doi.org/10.3233/CLO-2008-0440

Ejemplares similares

Mutant p53 targeting by the low molecular weight compound STIMA‐1
por: Zache, Nicole, et al.
Publicado: (2017)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, Xiaoxiao, et al.
Publicado: (2017)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2019)

PRIMA-1(MET )induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein
por: Stuber, György, et al.
Publicado: (2009)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
por: Menichini, Paola, et al.
Publicado: (2021)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
por: Haffo, Lena, et al.
Publicado: (2018)

Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
por: Zhang, Meiqiongzi, et al.
Publicado: (2018)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
por: Synnott, Naoise C., et al.
Publicado: (2018)

PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017)

p53 as a hub in cellular redox regulation and therapeutic target in cancer
por: Eriksson, Sofi E, et al.
Publicado: (2019)

PRIMA-1(Met) suppresses colorectal cancer independent of p53 by targeting MEK
por: Lu, Tao, et al.
Publicado: (2016)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

Prima tappa per AMS
Publicado: (2010)

PRIMA-1(met) (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
por: Li, Xiao-Lan, et al.
Publicado: (2015)

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN
por: Heldin, Angelos, et al.
Publicado: (2023)

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2021)

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2022)

Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine
por: Palomar-Siles, Mireia, et al.
Publicado: (2022)

PRIMA-1(MET)-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
por: Mlakar, Vid, et al.
Publicado: (2019)

In prima linea per l'Open Access
por: Altarelli, Guido
Publicado: (2005)

La prima donna del Gran Sasso
Publicado: (2009)

Targeting Oxidative Stress With Auranofin or Prima-1(Met) to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
por: Tessoulin, Benoit, et al.
Publicado: (2019)

Bertinoro: prima edizione della scuola internazionale INFN
Publicado: (2009)

Cern portavoce, Tenteremo prima accelerazione fascio particelle
Publicado: (2009)

Sensitivity to PRIMA-1(MET) is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status
por: Patyka, Mariia, et al.
Publicado: (2016)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
por: Ceder, Sophia, et al.
Publicado: (2020)

Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene
por: Palomar-Siles, Mireia, et al.
Publicado: (2023)

Come prima meglio di prima : commedia in tre atti /
por: Pirandello, Luigi, 1867-1936
Publicado: (1929)

Materia prima /
por: Blanco, Alberto, 1951-
Publicado: (1992)

Prima ventura
por: Galli-Carminati, Giuliana
Publicado: (1995)

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
por: Fransson, Åsa, et al.
Publicado: (2016)

Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1(MET)/APR-246
por: Aberdam, Edith, et al.
Publicado: (2020)

Mutant Mouse Models of Autism Spectrum Disorders
por: Provenzano, Giovanni, et al.
Publicado: (2012)

Mi prima Daniela /
por: Saucedo, Rosaura
Publicado: (1987)

La prima bela
por: Balzac, Honoré de, 1799-1850

Cannot write session to /tmp/vufind_sessions/sess_bd3v9iluamdeqkq7r60keesl4l